ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0928

Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Canadian Scleroderma Registry Database

Siobhan Deshauer1, Mats Junek2, Maggie Larche3 and Karen Beattie3, 1McMaster University, Hamilton, Canada, 2McMaster University, Hamilton, 3McMaster University, Hamilton, ON, Canada

Meeting: ACR Convergence 2020

Keywords: pregnancy, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is limited guidance for women with systemic sclerosis (SSc) in making decisions about pregnancy and informing them about their disease post-partum. Peripartum maternal and fetal complications have been reported, yet little is known about disease activity after pregnancy. We explored the trajectory of disease activity in women who experienced a pregnancy after scleroderma diagnosis and compared it with women who were nulliparous (NP).

Methods: We conducted a retrospective cohort study using data from a national SSc database. We identified two groups of women: those who were NP and those who experienced ≥ one pregnancy after their diagnosis (PAD) of scleroderma. Women with pre-pregnancy cardiac, lung or renal disease were excluded. Of these patients, 97% met ACR classification criteria. Descriptive statistics at the time of entry into the CSRG for each group are shown in Table 1. T-tests compared differences between groups. We used generalized estimating equations to test for the effect of pregnancy on the following outcomes over 8 years: force vital capacity, diffusing capacity of the lungs for carbon monoxide, right ventricular systolic pressure, glomerular filtration rate, antibody-status, active digital ulcers, physician global assessment of activity and physician global assessment of severity. We controlled for age, smoking and time since SSc diagnosis.

Results: At entry into CSRG there were 153 women in the NP group and 45 in the PAD group. After 6 years, n=48 in NP and n=21 in PAD decreased to 18 and 9 patients after 9 years, respectively. Prevalence of anti-topoisomerase positivity was 18.3% in NP and 12.5% in PAD. Differences in baseline characteristics included age of diagnosis (NP 38.8 years, SD 14; PAD 22.6, SD 6.8; p< 0.001), duration of disease (NP 9.6 years, SD 8.9; PAD 21.9, SD 9.6; p< 0.001) and inflammatory arthritis reported by rheumatologists (NP 41, 28%; PAD 22, 49%, p=0.009). Arthritis was not assessed over time.

There were no statistical differences between groups in the change of force vital capacity, diffusing capacity of the lungs for carbon monoxide, right ventricular systolic pressure, glomerular filtration rate, antibody-status, active digital ulcers, physician global assessment of activity and physician global assessment of severity over time.

Conclusion: This retrospective cohort study demonstrated that having ≥1 pregnancy after a diagnosis of systemic sclerosis did not appear to significantly impact renal, respiratory or global function outcomes over 10 years of follow-up. Study limitations include a small cohort size, retrospective data, unknown infertility rates and attrition. While our study offers a hopeful longer-term message for patients with SSc who are planning a pregnancy, physicians and patients should remain vigilant for potential post-partum complications.


Disclosure: S. Deshauer, None; M. Junek, None; M. Larche, AbbVie, 5, Amgen, 5, Boehringer-Ingelheim, 5, BMS, 5, Celgene, 5, Janssen, 5, Mallinckrodt, 5, Novartis, 5, Pfizer, 5, Roche, 5, Sandoz, 5, UCB, 5; K. Beattie, None.

To cite this abstract in AMA style:

Deshauer S, Junek M, Larche M, Beattie K. Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Canadian Scleroderma Registry Database [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/systemic-sclerosis-progression-and-pregnancy-a-hopeful-message-from-the-canadian-scleroderma-registry-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-sclerosis-progression-and-pregnancy-a-hopeful-message-from-the-canadian-scleroderma-registry-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology